Obesity and Type 2 Diabetes – (STEP UP)

People with Type 2 diabetes (T2D) often have multiple unmet medical needs related to cardiovascular risks, including hypertension and dyslipidaemia. It has been consistently demonstrated that weight loss in participants with T2D has a beneficial impact not only on glycaemic control, but also on other cardiovascular risk markers.  The risk of obesity-related complications increases with increasing BMI, and weight loss can have significant health benefits in terms of slowing the progression of T2D. 

This study will look at how the investigational dose of semaglutide works in helping people with excess body weight and type 2 diabetes lose weight and better control blood sugar levels. This will be compared to a placebo (no active ingredient) and a lower dose of semaglutide. 

This study will last about 1 ½ years. 

A few qualifications to participate are: 

• Male or female above or equal to 18 years of age
• Diagnosed with T2D greater than or equal to 180 days prior to screening
• History of at least one self-reported unsuccessful dietary effort to lose body weight
• Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs